Results 181 to 190 of about 170,256 (261)

Dupilumab‐Associated Erythema Multiforme‐Like Eruption With Lichenoid Histology in a Paediatric Patient: A Case Report

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Dupilumab‐associated erythema multiforme and lichenoid eruptions have been previously reported as rare dermatological adverse events. We present an atypical paediatric case of a dupilumab‐associated erythema multiforme‐like eruption in a 5‐year‐old male eczema patient, who developed erythematous targetoid papules and plaques over the upper and
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Narinder Kaur, Miriam Fewtrell, Li‐Chuen Wong   +7 more
wiley   +1 more source

Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients

Allergy, EarlyView.
Skin tape strip lipidomic analysis revealed preexisting skin barrier lipid abnormalities at day 0 that were further exacerbated after 6 weeks of CPI treatment. Significant changes in skin (but not plasma) proinflammatory cytokines were identified in future ircAE patients after 6 weeks of CPI immunotherapy.
Taras Lyubchenko, Evgeny Berdyshev, Ryan M. Weight, Olivia Xiao, Neil J. Shah, Alina Markova, Mario E. Lacouture, Jeffrey A. Kern, Elena Goleva, Donald Y. M. Leung   +9 more
wiley   +1 more source

First-line Enfortumab Vedotin Plus Pembrolizumab in Platinum-ineligible Advanced Urothelial Carcinoma. [PDF]

Cancer Diagn Progn
Kaneko GO, Igarashi D, Shirotake S.
europepmc   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam, M Figura, J Heyer, S Lieber, M Huber, KL Loveland, HC Schuppe, Daniela Fietz   +7 more
wiley   +1 more source

Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. [PDF]

Breast Cancer Res Treat
Kroll MR, Schroeder MC, Neuner JM, Viyyuri BR, Ravindra A, McDougall D, Chapman CG, Fleege NMG, Chrischilles EA, Song X, Phadke S.   +10 more
europepmc   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports. [PDF]

Cancer Rep (Hoboken)
Godin SL, Kingma T, Pillai A, Kholoki O, Kim AS.   +4 more
europepmc   +1 more source

Pembrolizumab plus enfortumab vedotin in urothelial cancer

The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive ...
Fiala, Ondrej, Bellmunt, Joaquim, Santoni, Matteo, Bamias, Aristotelis, Buti, Sebastiano, Santoni, Angela, Takeshita, Hideki, Massari, Francesco, Cerbone, Linda, Mollica, Veronica   +9 more
core  

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

An atypical presentation of Pembrolizumab-induced bullous pemphigoid in a patient with uterine serous carcinoma. [PDF]

Gynecol Oncol Rep
Chen RY, Vasavda C, Imadojemu S, Liu SW, Campos SM.   +4 more
europepmc   +1 more source